A large biotech company will maintain patent protection on one of its key products for the next several years following a federal court’s ruling that a biosimilar challenger infringed on its patents. https://medcitynews.com/2020/07/sandoz-loses-challenge-to-patent-on-amgens-5-2b-autoimmune-drug-may-appeal-to-supreme-court/?rf=1

In November 2019, the China National Intellectual Property Agency (CNIPA) issued new patent examination guidelines for applying China’s “inventive step” requirement, the patentability standard roughly equivalent to the U.S. patent requirement of “nonobviousness.” https://www.law.com/thelegalintelligencer/2020/06/26/application-of-invention-concept-after-new-china-patent-examination-guidelines/

Real-party-in-interest disputes can be hotly contested before the Board. An order from the Northern District of Illinois shows that these disputes can have larger significance and impact petitioners in litigation. https://www.ipwatchdog.com/2020/03/30/happens-board-not-stay-board-patent-owners-can-leverage-ipr-proceedings-litigation/id=120222/

Biopharmaceutical firm Biocon on March 11 said its partner Mylan has won a US court ruling that invalidated a Sanofi patent on an insulin glargine device. https://www.moneycontrol.com/news/business/companies/biocon-mylan-win-patent-violation-suit-filed-by-sanofi-in-us-over-insulin-glargine-device-5023301.html

There were major changes in the patent marking laws in 2011, when the America Invents Act (AIA) went into effect, that impact how patent owners communicate, or mark, their devices to identify applicable patents that affect affects how much they are eligible to receive in damages in the event of... Read More